ID   CH22
AC   CVCL_C159
SY   CH-22
DR   Wikidata; Q54811631
RX   PubMed=22504929;
RX   PubMed=28606919;
WW   https://www.chordomafoundation.org/researchers/disease-models/ch22/
CC   Doubling time: 33 hours (PubMed=22504929); 2.3 days (Chordoma Foundation).
CC   Miscellaneous: STR profile from personal communication of Duan Z.
CC   Derived from site: In situ; Bone, sacrum; UBERON=UBERON_0003690.
ST   Source(s): Direct_author_submission
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 10,14
ST   D16S539: 12,13
ST   D5S818: 10,12
ST   D7S820: 10,11
ST   TH01: 6
ST   TPOX: 8,11
ST   vWA: 17
DI   NCIt; C129927; Sacral chordoma
DI   ORDO; Orphanet_178; Chordoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   56Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 02-05-24; Version: 15
//
RX   PubMed=22504929; DOI=10.1002/jor.22113;
RA   Liu X.-Z., Nielsen G.P., Rosenberg A.E., Waterman P.R., Yang W.,
RA   Choy E., Sassi S., Yang S.-H., Harmon D.C., Yang C., Schwab J.H.,
RA   Kobayashi E., Mankin H.J., Xavier R.J., Weissleder R., Duan Z.-F.,
RA   Hornicek F.J.;
RT   "Establishment and characterization of a novel chordoma cell line:
RT   CH22.";
RL   J. Orthop. Res. 30:1666-1673(2012).
//
RX   PubMed=28606919; DOI=10.1158/1078-0432.CCR-17-0177;
RA   Chen H., Garbutt C.C., Spentzos D., Choy E., Hornicek F.J.,
RA   Duan Z.-F.;
RT   "Expression and therapeutic potential of SOX9 in chordoma.";
RL   Clin. Cancer Res. 23:5176-5186(2017).
//